Metoclopramide: Nursing Drug Guide, Tardive Dyskinesia & Hold Rules

Metoclopramide is available generically and as Reglan (tablets, orally disintegrating tablets, oral solution, and injection). Brand and generic products are not interchangeable on the MAR without prescriber verification—concentrations and routes differ.

Common presentations: 5 mg and 10 mg tablets; 5 mg/mL injection (IV/IM). Not interchangeable with: ondansetron or other 5-HT₃ antiemetics—different mechanisms, risks, and monitoring.

Metoclopramide increases upper GI motility and lower esophageal sphincter tone. Tablet labeling focuses on reflux and diabetic gastroparesis; injection labeling also includes chemotherapy-related and postoperative nausea/vomiting when oral therapy is not feasible.

↔On a small screen, swipe or scroll sideways to see the full table.

Pediatrics: Metoclopramide tablets are not recommended in pediatric patients due to TD, other EPS, and neonatal methemoglobinemia risk per labeling. Injection has additional pediatric oncology dosing—follow specialized protocols only.

Metoclopramide is a dopamine-2 receptor antagonist that sensitizes GI tissues to acetylcholine, increasing gastric antral contractions, relaxing the pylorus and duodenal bulb, and accelerating gastric emptying and intestinal transit. It increases lower esophageal sphincter tone. Anticholinergic drugs can abolish the motility effect.

Because it blocks central dopamine pathways, metoclopramide can cause extrapyramidal symptoms, tardive dyskinesia, hyperprolactinemia, and (rarely) neuroleptic malignant syndrome—nurses must balance prokinetic benefit against neurologic risk on every shift.

All doses below are from current U.S. metoclopramide tablet and injection prescribing information. Verify indication, route, and renal/hepatic adjustments on the MAR.

Elderly and organ impairment

Consider starting 5 mg four times daily in older adults and titrate based on response and tolerability. Reduce dose when creatinine clearance is ≤60 mL/min, in moderate/severe hepatic impairment (Child-Pugh B or C), in CYP2D6 poor metabolizers, and with strong CYP2D6 inhibitors (e.g., fluoxetine)—see labeling tables for specific reduced schedules.

Injection-specific notes

• When severe nausea prevents oral therapy, injection may be given IM or IV for up to 10 days before switching to tablets (gastroparesis pathway per tablet labeling)
• Undiluted IV doses should be administered slowly (about 1–2 minutes for 10 mg) because rapid injection may cause intense anxiety/restlessness per injection labeling
• High emetogenic chemotherapy regimens may use weight-based IV dosing (e.g., 2 mg/kg for initial doses in some protocols)—follow oncology orders and injection labeling only

Missed dose: Give when remembered if not near the next scheduled dose; do not double. If the patient is near the 12-week limit, clarify continuation with prescriber/pharmacy before resuming after a lapse.

Pretreatment checks

• Confirm start date and planned duration—flag courses approaching 12 weeks
• Screen for GI bleeding, mechanical obstruction, or perforation—prokinetics are contraindicated when stimulation of motility is dangerous
• Complete medication reconciliation for antipsychotics, antiparkinsonian drugs, MAO inhibitors, CNS depressants, and anticholinergic/antiperistaltic agents
• History of TD, dystonic reaction to metoclopramide, Parkinson disease, epilepsy, pheochromocytoma, or depression (avoid use per labeling)
• Check renal function (eGFR / creatinine clearance) and hepatic status before repeat or high-frequency dosing
• Baseline EPS assessment: observe face, tongue, jaw, and extremities; ask about restlessness or new movement habits

Contraindications

• History of tardive dyskinesia or dystonic reaction to metoclopramide
• GI hemorrhage, mechanical obstruction, or perforation
• Pheochromocytoma or other catecholamine-releasing paragangliomas
• Epilepsy (may increase seizure frequency/severity)
• Hypersensitivity to metoclopramide (including angioedema/bronchospasm)

Warnings and cautions

• Tardive dyskinesia—discontinue immediately if involuntary movements develop; drug may partially mask TD signs while disease progresses
• Other EPS—dystonia more common in adults <30 years and at higher-than-recommended doses; parkinsonian symptoms may appear within first 6 months
• Neuroleptic malignant syndrome—hyperpyrexia, rigidity, altered mental status, autonomic instability
• Depression/suicidality—avoid in patients with depression history
• Hypertension—may elevate BP; avoid with MAO inhibitors; discontinue with rapid BP rise
• Fluid retention—transient aldosterone increase; caution in cirrhosis or heart failure
• Hyperprolactinemia—galactorrhea, amenorrhea, gynecomastia, impotence possible

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Oral: Give 30 minutes before meals and at bedtime for scheduled regimens. Tablets are light-sensitive—inspect for discoloration or particulate matter per labeling.

• IV: Administer slowly; undiluted 10 mg over about 1–2 minutes per injection labeling to reduce acute anxiety/restlessness
• IM: Standard adult dose often 10 mg near end of surgery for postoperative nausea prophylaxis per injection labeling
• Switching routes: When IV/IM used for gastroparesis because of severe vomiting, transition to oral tablets as soon as the patient can tolerate PO
• Use IV bolus administration standards and continuous cardiorespiratory monitoring during IV doses

• Reduced nausea and vomiting with improved oral intake
• Decreased postprandial fullness, bloating, and reflux symptoms in gastroparesis/GERD
• Improved gastric emptying markers when monitored (residual volumes, patient-reported early satiety)
• Chemotherapy or postoperative pathways: fewer emetic episodes per institutional scales
• Mild drowsiness or restlessness may occur in approximately 10% of patients at 10 mg four times daily per labeling—distinguish expected effects from EPS

• Involuntary lip smacking, tongue protrusion, chewing movements, or facial grimacing—suspect tardive dyskinesia; stop drug and notify prescriber immediately
• Acute neck twisting (torticollis), oculogyric crisis, jaw trismus, or stridor/dyspnea—acute dystonic reaction; urgent prescriber response; diphenhydramine or benztropine may be ordered
• High fever, rigid muscles, altered mental status, tachycardia, labile BP—suspect neuroleptic malignant syndrome; emergency escalation
• New parkinsonian gait, mask-like face, or cogwheel rigidity—hold drug and notify prescriber
• Severe restlessness with inability to sit still (akathisia)—do not automatically increase dose
• Rapid BP rise, severe headache, or suspected pheochromocytoma crisis—stop drug and escalate
• Worsening abdominal pain, distention, or bilious emesis—possible obstruction; hold prokinetic
• New suicidal ideation or severe mood change—hold and mental health escalation per protocol

↔On a small screen, swipe or scroll sideways to see the full table.

Overdose may cause drowsiness, disorientation, extrapyramidal reactions, methemoglobinemia, and death. NMS has been reported with overdose and with interacting dopamine-blocking drugs.

Management (per labeling)

• No specific antidote for metoclopramide overdosage—supportive care and toxicology consultation per facility protocol
• Treat EPS with diphenhydramine or benztropine as prescriber directs
• NMS: stop nonessential drugs, intensive monitoring, treat comorbid conditions and hyperthermia per emergency protocol
• Methemoglobinemia: IV methylene blue may be used except in G6PD deficiency, where methylene blue may cause fatal hemolytic anemia
• Hemodialysis and peritoneal dialysis do not remove significant amounts of metoclopramide

• Metoclopramide vs metformin, methotrexate, metoprolol—verify drug name, indication, and dose at every shift handoff and ADC scan
• Metoclopramide vs ondansetron—different antiemetic class; do not substitute without prescriber order
• Reglan vs similar-sounding GI drugs—read label aloud; use barcode scanning when available
• Duration errors—automatically renew orders can extend therapy past 12 weeks; pharmacy and nursing should flag stop dates
• mg vs mL for injection—5 mg/mL concentration; calculate total mg every time

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Movement disorder screen each shift: face, tongue, jaw, fingers, toes; gait and restlessness
• Therapy duration—document weeks on drug; alert prescriber before 12-week limit
• GI symptoms: vomiting character, abdominal exam, bowel sounds, NG output
• Vitals and orthostatics when sedated or on concurrent CNS depressants
• Renal/hepatic labs (basic metabolic panel) for long courses or dose adjustments
• Blood glucose in diabetes when gastric emptying improves
• Consider QTc monitoring when patient has arrhythmia risk factors and receives other QT-prolonging therapy (not a primary labeled warning for metoclopramide—follow institutional policy)
• Mental status and mood—especially with depression history

Document

• Indication, start date, planned duration, dose, route, and response
• EPS assessments and patient/caregiver teaching on involuntary movements
• Hold events, obstruction workup, and prescriber/pharmacy notifications
• Anti-emetic effectiveness and intake/output trends

• “Take this medicine 30 minutes before meals as directed. Do not use it longer than your prescriber recommends—usually no more than 12 weeks unless they tell you otherwise.”
• Report lip smacking, tongue thrusting, chewing motions, puckering, or movements you cannot control immediately—these may be tardive dyskinesia and the drug may need to be stopped permanently.
• Report neck stiffness, eye rolling, trouble speaking, severe restlessness, high fever with muscle stiffness, or confusion urgently.
• This medicine may cause drowsiness—do not drive until you know how you respond.
• Report worsening abdominal pain, bloating, or green/bilious vomiting before taking the next dose.
• If breastfeeding, watch the infant for unusual movements or increased gas; contact your care team with concerns.

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and oncology/perioperative pathways.

↔On a small screen, swipe or scroll sideways to see the full table.

Practice NCLEX-style clinical judgment practice for metoclopramide with a tabbed gastroparesis case (MAR, labs, history, nursing notes), then priority action, cue recognition, trend interpretation, documentation cloze, clinical judgment, and matrix urgency—recognise TD/EPS cues → analyse duration risk → prioritise holds → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.